Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction.

A whole-genome tumor-informed assay tracking 1,800 variants was applied to 2,994 plasma samples from 431 people with non-small cell lung cancer in TRACERx, and detection below 80 parts per million was prognostic before and after surgery.

CellPubMed 41205598DOI 10.1016/j.cell.2025.10.020